RA
INSY

Royce & Associates’s Insys Therapeutics, Inc. INSY Stock Holding History

Royce & Associates’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-138,240
Closed -$1.61M – 1498
2013
Q3 		$1.61M Sell
138,240
-611,760
-82% -$5.02M ﹤0.01% 1108
2013
Q2 		$3.46M Buy
+750,000
New +$2.75M 0.01% 938

Other funds holding INSY

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Royce & Associates's INSY Position: Q4 2013 in Review

Royce & Associates sold out of Insys Therapeutics, Inc. (INSY) in Q4 2013, closing a stake of 138,240 shares — an estimated $1.61M sold.

Royce & Associates first reported a position in INSY in Q2 2013 and held it in 2 quarters. The position peaked at $3.46M in Q2 2013. 86 funds tracked by Wall St. Rank hold INSY as of Q4 2013.

  • Royce & Associates reported no remaining Insys Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Royce & Associates sold 138,240 Insys Therapeutics, Inc. shares in Q4 2013, an estimated $1.61M.
  • Royce & Associates first reported a position in Insys Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Royce & Associates's Insys Therapeutics, Inc. position peaked at $3.46M in Q2 2013.
  • 86 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2013.

Based on Royce & Associates's 13F filing for Q4 2013, filed 10 Feb 2014.